{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:27Z","timestamp":1789480287950,"version":"build-2803163510"},"reference-count":40,"publisher":"American Society of Hematology","issue":"26","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by monoclonal immunoglobulin M autoantibodies that bind to red blood cells and trigger hemolysis through activation of the classical complement pathway. Cold agglutinins are produced by a clonal population of lymphocytes, recognized by the World Health Organization as a low-grade lymphoproliferative disorder. Traditional therapy relied on B-cell\u2013targeted immunosuppression with rituximab, which mainly yielded partial responses in approximately half of the patients. The combination of rituximab with fludarabine or bendamustine significantly increased and prolonged response rates, although with a substantial infectious risk. Sutimlimab, the first C1s complement inhibitor, has shown efficacy in rapidly and sustainably increasing hemoglobin levels, reducing hemolysis, and significantly improving quality of life. However, the drug does not act on the B-cell clone and does not decrease cold agglutinins. Therefore, several unmet needs remain, including identifying patients who can discontinue sutimlimab while maintaining remission, developing combination strategies effective against cold-induced symptoms, and improving infection prevention and control of hemolytic flares. This perspective article briefly recapitulates the pathophysiology of CAD, outlines the evolution of its treatment landscape, and focuses on the role of sutimlimab, including its clinical positioning, therapeutic benefits, and management considerations, offering insights into optimizing care for patients with this challenging condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033150","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:00:22Z","timestamp":1774890022000},"page":"3135-3143","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Sutimlimab vs B-cell\u2013targeted therapy in cold agglutinin disease: which is the optimal approach?"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"first","affiliation":[{"name":"1Dipartimento di Oncologia ed Emato-Oncologia, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"2Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Broome","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2026062511215601900_bib1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune hemolytic anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"2026062511215601900_bib2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026062511215601900_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/17474086.2024.2366540","article-title":"The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease","volume":"17","author":"Barcellini","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2026062511215601900_bib4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"2026062511215601900_bib5","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","volume":"20","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026062511215601900_bib6","doi-asserted-by":"crossref","first-page":"791429","DOI":"10.3389\/fimmu.2021.791429","article-title":"Complement mediated hemolytic anemias in the COVID-19 era: case series and review of the literature","volume":"12","author":"Fattizzo","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"2026062511215601900_bib7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2026062511215601900_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"2026062511215601900_bib9","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/bloodadvances.2023011798","article-title":"Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis","volume":"8","author":"Fattizzo","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2026062511215601900_bib10","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2026062511215601900_bib11","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2026062511215601900_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2026062511215601900_bib13","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026062511215601900_bib14","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ajh.27493","article-title":"Parsaclisib for the treatment of primary autoimmune hemolytic anemia: results from a phase 2, open-label study","volume":"99","author":"Barcellini","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2026062511215601900_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2026062511215601900_bib16","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2026062511215601900_bib17","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2026062511215601900_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.2023022549","article-title":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","volume":"145","author":"Roman","year":"2025","journal-title":"Blood"},{"key":"2026062511215601900_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajh.70147","article-title":"Iptacopan for immune thrombocytopenia and cold agglutinin disease: a global phase 2 basket clinical trial","volume":"101","author":"R\u00f6th","year":"2026","journal-title":"Am J Hematol"},{"issue":"9","key":"2026062511215601900_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2026062511215601900_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","article-title":"Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program","volume":"4","author":"Gelbenegger","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2026062511215601900_bib22","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/bjh.18289","article-title":"Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: a phase I, open-label, extension trial","volume":"198","author":"Gelbenegger","year":"2022","journal-title":"Br J Haematol"},{"issue":"14","key":"2026062511215601900_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"2026062511215601900_bib24","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3324\/haematol.2021.279812","article-title":"Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results","volume":"107","author":"Roth","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"2026062511215601900_bib25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.26965","article-title":"Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease","volume":"98","author":"R\u00f6th","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2026062511215601900_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"2026062511215601900_bib27","doi-asserted-by":"crossref","first-page":"102733","DOI":"10.1016\/j.eclinm.2024.102733","article-title":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study part B","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2026062511215601900_bib28","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/bloodadvances.2022008574","article-title":"Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease","volume":"7","author":"Gelbenegger","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026062511215601900_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.1800998","article-title":"C1s Inhibition by BIVV009 (sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro","volume":"202","author":"Nikitin","year":"2019","journal-title":"J Immunol"},{"issue":"19","key":"2026062511215601900_bib30","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1182\/bloodadvances.2022009318","article-title":"Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up [published correction appears in Blood Adv. 2024;8(11):2650]","volume":"7","author":"R\u00f6th","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026062511215601900_bib31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00277-022-04948-y","article-title":"Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study [published correction appears in Ann Hematol. 2024;103(5):1803]","volume":"101","author":"R\u00f6th","year":"2022","journal-title":"Ann Hematol"},{"issue":"3","key":"2026062511215601900_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ejh.13903","article-title":"Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: results from the randomised, placebo-controlled, phase 3 CADENZA study","volume":"110","author":"R\u00f6th","year":"2023","journal-title":"Eur J Haematol"},{"key":"2026062511215601900_bib33","doi-asserted-by":"crossref","first-page":"102732","DOI":"10.1016\/j.eclinm.2024.102732","article-title":"Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2026062511215601900_bib34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ajh.27234","article-title":"COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab","volume":"99","author":"Fattizzo","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"2026062511215601900_bib35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12185-024-03842-9","article-title":"Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease","volume":"120","author":"Miyakawa","year":"2024","journal-title":"Int J Hematol"},{"issue":"suppl 1","key":"2026062511215601900_bib36","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood-2025-1100","article-title":"Real world use of sutimlimab in patients with cold agglutinin disease: an international study [abstract]","volume":"146","author":"Fattizzo","year":"2025","journal-title":"Blood"},{"key":"2026062511215601900_bib37","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"2","key":"2026062511215601900_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Schollkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2026062511215601900_bib39","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG Clinical Trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026062511215601900_bib40","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood-2024-199637","article-title":"Ictacopan monotherapy in patients with cold agglutinin disease: phase II study results [abstract]","volume":"144","author":"R\u00f6th","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/26\/3135\/2528541\/blood_bld-2026-033150-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/26\/3135\/2528541\/blood_bld-2026-033150-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:22:07Z","timestamp":1782400927000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/26\/3135\/567481\/Sutimlimab-vs-B-cell-targeted-therapy-in-cold"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":40,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033150","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,25]]},"published":{"date-parts":[[2026,6,25]]}}}